1
|
Muto Y, Kinjyo K, Asano Y. Successful treatment of Darier's disease with apremilast and review of reported cases. J Dermatol 2024. [PMID: 39031325 DOI: 10.1111/1346-8138.17392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2024] [Revised: 06/24/2024] [Accepted: 07/08/2024] [Indexed: 07/22/2024]
Abstract
Darier's disease (DD) is a rare autosomal dominant genetic disorder caused by a mutation in ATP2A2, which encodes calcium (Ca2+) ATPase pumps in the endoplasmic reticulum. In this report, we present the first documented case in Japan successfully treated with apremilast. An 18-year-old female presented with red or brown hyperkeratotic papules and plaques on her head, neck, and chest. Histopathological examination revealed a hyperkeratotic, acanthotic epidermis, along with suprabasal acantholysis characterized by corps ronds and grains. Exome sequencing of DNA from peripheral blood mononuclear cells identified a missense mutation in ATP2A2. Based on the above results, we diagnosed her with DD despite the absence of a family history. Given the effectiveness of apremilast, a phosphodiesterase 4 inhibitor, in treating Hailey-Hailey disease (HHD), a genetically related disorder involving ATPases in epidermal calcium channels, we opted for apremilast therapy. Eight weeks post-initiation, significant improvement was observed in the patient's skin lesions on the head, neck, and chest. In this paper, we discuss the successful treatment of DD and HHD cases with apremilast, providing insights into its therapeutic potential, and offer a comprehensive review.
Collapse
Affiliation(s)
- Yusuke Muto
- Department of Dermatology, South Miyagi Medical Center, Sibata, Japan
| | - Kengo Kinjyo
- Department of Dermatology, South Miyagi Medical Center, Sibata, Japan
| | - Yoshihide Asano
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan
| |
Collapse
|
2
|
Afroditi Kleidona I, Agiasofitou E, Tsiogka A, Chorti M, Gregoriou S, Stratigos A, Rigopoulos D, Kontochristopoulos G. Darier disease responding to apremilast: Report of two cases. Indian J Dermatol Venereol Leprol 2024; 0:1-3. [PMID: 38314981 DOI: 10.25259/ijdvl_83_2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Accepted: 08/24/2023] [Indexed: 02/07/2024]
Affiliation(s)
- Ileana Afroditi Kleidona
- Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Faculty of Medicine, Andreas Sygros Hospital, Athens, Greece
| | - Efthymia Agiasofitou
- Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Faculty of Medicine, Andreas Sygros Hospital, Athens, Greece
| | - Aikaterini Tsiogka
- Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Faculty of Medicine, Andreas Sygros Hospital, Athens, Greece
| | - Marina Chorti
- Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Faculty of Medicine, Andreas Sygros Hospital, Athens, Greece
| | - Stamatios Gregoriou
- Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Faculty of Medicine, Andreas Sygros Hospital, Athens, Greece
| | - Alexander Stratigos
- Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Faculty of Medicine, Andreas Sygros Hospital, Athens, Greece
| | - Dimitrios Rigopoulos
- Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Faculty of Medicine, Andreas Sygros Hospital, Athens, Greece
| | - George Kontochristopoulos
- Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Faculty of Medicine, Andreas Sygros Hospital, Athens, Greece
| |
Collapse
|
3
|
Yamaga M, Miyauchi T, Peh JT, Itamoto S, Mai Y, Iwata H, Nomura T, Ujiie H. Case report: Difference in outcomes between two cases of Hailey-Hailey disease treated with apremilast. Front Genet 2022; 13:884359. [PMID: 36276960 PMCID: PMC9583697 DOI: 10.3389/fgene.2022.884359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2022] [Accepted: 08/23/2022] [Indexed: 11/25/2022] Open
Abstract
Hailey-Hailey disease (HHD) is a rare autosomal dominant acantholytic dermatosis clinically characterized by recurrent erythematous plaques and erosions mainly on the intertriginous regions. Although HHD seriously affects quality of life, conventional treatments often fail to provide long-term relief for most patients. The effectiveness of apremilast, a phosphodiesterase-4 inhibitor, against severe HHD was first reported in 2018, and after further testing, this agent is currently expected to be established as an efficacious and safe therapeutic option. Here we report two cases of HHD treated with apremilast which showed opposite outcomes. Although the case with extremely severe symptoms showed remarkable and long-lasting improvement with apremilast used after acute treatment with oral corticosteroid, the other case, with milder symptoms treated only with apremilast, showed no improvement. Our transcriptome analysis using skin samples collected prior to apremilast administration revealed the involvement of the NF-κB signaling pathway, which is related to the responses to bacteria and other organisms. However, this pathway was more strongly activated in case 2 than in case 1, suggesting that the steroid treatment preceding apremilast may have been effective and supportive in the apremilast-responding case. One of the two cases highlights the potential of apremilast as a treatment option for HHD, but the other underlines the difficulties in managing HHD and the complexity of the disease background. The accumulation of cases and larger clinical studies are expected to precisely evaluate the safety and efficacy of apremilast, and the potential for therapies in combination with conventional treatments.
Collapse
Affiliation(s)
- Misako Yamaga
- Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Toshinari Miyauchi
- Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
- *Correspondence: Toshinari Miyauchi,
| | - Jin Teng Peh
- Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Sota Itamoto
- Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Yosuke Mai
- Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Hiroaki Iwata
- Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| | - Toshifumi Nomura
- Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
- Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
| | - Hideyuki Ujiie
- Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
| |
Collapse
|
4
|
Scarabello A, Pulvirenti C, Adebanjo GAR, Parisella FR, Chello C, Tammaro A. Photodynamic therapy with 5 aminolaevulinic acid: a promising therapeutic option for the treatment of Hailey-Hailey Disease. Photodiagnosis Photodyn Ther 2022; 38:102794. [PMID: 35247621 DOI: 10.1016/j.pdpdt.2022.102794] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 02/20/2022] [Accepted: 02/28/2022] [Indexed: 11/28/2022]
Affiliation(s)
- Alessandra Scarabello
- Dermatology Unit, National Institute of Infectious Diseases L. Spallanzani, Rome, Italy
| | - Carola Pulvirenti
- Dermatology Unit, National Institute of Infectious Diseases L. Spallanzani, Rome, Italy
| | | | | | - Camilla Chello
- NESMOS Dermatology Department, Sapienza University of Rome, Rome, Italy
| | - Antonella Tammaro
- NESMOS Dermatology Department, Sapienza University of Rome, Rome, Italy.
| |
Collapse
|